These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 28657611)

  • 1. CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL.
    Jordaan S; Chetty S; Mungra N; Koopmans I; van Bommel PE; Helfrich W; Barth S
    Biomedicines; 2017 Jun; 5(3):. PubMed ID: 28657611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein.
    Amoury M; Mladenov R; Nachreiner T; Pham AT; Hristodorov D; Di Fiore S; Helfrich W; Pardo A; Fey G; Schwenkert M; Thepen T; Kiessling F; Hussain AF; Fischer R; Kolberg K; Barth S
    Int J Cancer; 2016 Aug; 139(4):916-27. PubMed ID: 27037627
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.
    Ilieva KM; Cheung A; Mele S; Chiaruttini G; Crescioli S; Griffin M; Nakamura M; Spicer JF; Tsoka S; Lacy KE; Tutt ANJ; Karagiannis SN
    Front Immunol; 2017; 8():1911. PubMed ID: 29375561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
    Hoffmann RM; Crescioli S; Mele S; Sachouli E; Cheung A; Chui CK; Andriollo P; Jackson PJM; Lacy KE; Spicer JF; Thurston DE; Karagiannis SN
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32331483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
    Beard RE; Zheng Z; Lagisetty KH; Burns WR; Tran E; Hewitt SM; Abate-Daga D; Rosati SF; Fine HA; Ferrone S; Rosenberg SA; Morgan RA
    J Immunother Cancer; 2014; 2():25. PubMed ID: 25197555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chondroitin Sulfate Proteoglycan 4 (CSPG4) as an Emerging Target for Immunotherapy to Treat Melanoma.
    Chen X; Habib S; Alexandru M; Chauhan J; Evan T; Troka JM; Rahimi A; Esapa B; Tull TJ; Ng WZ; Fitzpatrick A; Wu Y; Geh JLC; Lloyd-Hughes H; Palhares LCGF; Adams R; Bax HJ; Whittaker S; Jacków-Malinowska J; Karagiannis SN
    Cancers (Basel); 2024 Sep; 16(19):. PubMed ID: 39409881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific Antibody Approach for Improved Melanoma-Selective PD-L1 Immune Checkpoint Blockade.
    Koopmans I; Hendriks MAJM; van Ginkel RJ; Samplonius DF; Bremer E; Helfrich W
    J Invest Dermatol; 2019 Nov; 139(11):2343-2351.e3. PubMed ID: 31128201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CSPG4 as a target of antibody-based immunotherapy for malignant mesothelioma.
    Rivera Z; Ferrone S; Wang X; Jube S; Yang H; Pass HI; Kanodia S; Gaudino G; Carbone M
    Clin Cancer Res; 2012 Oct; 18(19):5352-63. PubMed ID: 22893632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional characterization of an scFv-Fc antibody that immunotherapeutically targets the common cancer cell surface proteoglycan CSPG4.
    Wang X; Katayama A; Wang Y; Yu L; Favoino E; Sakakura K; Favole A; Tsuchikawa T; Silver S; Watkins SC; Kageshita T; Ferrone S
    Cancer Res; 2011 Dec; 71(24):7410-22. PubMed ID: 22021902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapeutic Targeting of NG2/CSPG4 in Solid Organ Cancers.
    Zhang H; Wu Z; Hu D; Yan M; Sun J; Lai J; Bai L
    Vaccines (Basel); 2022 Jun; 10(7):. PubMed ID: 35891187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSPG4 in cancer: multiple roles.
    Wang X; Wang Y; Yu L; Sakakura K; Visus C; Schwab JH; Ferrone CR; Favoino E; Koya Y; Campoli MR; McCarthy JB; DeLeo AB; Ferrone S
    Curr Mol Med; 2010 Jun; 10(4):419-29. PubMed ID: 20455858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-chondroitin sulfate proteoglycan 4-specific antibodies modify the effects of vemurafenib on melanoma cells differentially in normoxia and hypoxia.
    Pucciarelli D; Lengger N; Takacova M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
    Int J Oncol; 2015 Jul; 47(1):81-90. PubMed ID: 25997619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
    Nota SPFT; Osei-Hwedieh DO; Drum DL; Wang X; Sabbatino F; Ferrone S; Schwab JH
    Front Oncol; 2022; 12():939166. PubMed ID: 36110930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.
    Kurokawa T; Imai K
    Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(5):293-308. PubMed ID: 38735753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors.
    Wang Y; Geldres C; Ferrone S; Dotti G
    Expert Opin Ther Targets; 2015; 19(10):1339-50. PubMed ID: 26190756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chondroitin sulfate proteoglycan-4 does not protect melanoma cells during inhibition of PI3K and mTOR pathways.
    Javaid S; Terai K; Dudek AZ
    Anticancer Res; 2015 Mar; 35(3):1279-84. PubMed ID: 25750275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-Expression and Combined Prognostic Value of CSPG4 and PDL1 in
    Hu ZY; Zheng C; Yang J; Ding S; Tian C; Xie N; Xue L; Wu M; Fu S; Rao Z; Price MA; McCarthy JB; Ouyang Q; Lin J; Deng X
    Front Oncol; 2022; 12():804466. PubMed ID: 35280756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.
    Price MA; Colvin Wanshura LE; Yang J; Carlson J; Xiang B; Li G; Ferrone S; Dudek AZ; Turley EA; McCarthy JB
    Pigment Cell Melanoma Res; 2011 Dec; 24(6):1148-57. PubMed ID: 22004131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
    Yang J; Price MA; Wanshura LEC; He J; Yi M; Welch DR; Li G; Conner S; Sachs J; Turley EA; McCarthy JB
    Melanoma Res; 2019 Aug; 29(4):365-375. PubMed ID: 31140988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma.
    Mayayo SL; Prestigio S; Maniscalco L; Rosa G; Aricò A; Maria R; Cavallo F; Ferrone S; Buracco P; Iussich S
    Vet J; 2011 Nov; 190(2):e26-e30. PubMed ID: 21482159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.